AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis
Journal of Allergy and Clinical Immunology · 2026-11 · 158 (5) · 1333-1346
DOI: 10.1016/j.jaci.2026.06.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-11. Verfasst von Seung Taek Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Jeonbuk National University Medical School, Jeonju, Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, B-Lymphocytes, Regulatory, AMP-Activated Protein Kinases. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute.
Abstract (Originalsprache)
BACKGROUND: Atopic dermatitis (AD) is characterized by dysregulated immune responses and persistent inflammation. Regulatory B (Breg) cells suppress inflammation, but the metabolic mechanisms constraining their function in AD remain unclear. OBJECTIVE: We sought to define whether immunometabolic regulation governs Breg cell differentiation and function in AD. METHODS: Mouse and human B cells were stimulated with the adenosine monophosphate-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) under inflammatory conditions, with genetic and pharmacologic perturbations. Functional and mechanistic analyses were performed with coculture systems, a 2,4-dinitrochlorobenzene and Dermatophagoides farinae extract-induced murine model of AD, adoptive transfer approaches, adoptive transfer, and human peripheral blood mononuclear cells from patients with AD. RESULTS: AICAR treatment or adoptive transfer of AICAR-induced Breg cells significantly attenuated AD-like inflammation, whereas AMPK inhibition or IL-10 blockade abrogated these effects. Mechanistically, AICAR induced IL-10-producing Breg cells through AMPK-dependent suppression of mTOR signaling and mitochondrial reactive oxygen species while preserving oxidative phosphorylation. This reprogramming selectively enhanced regulatory B-cell function and suppressed STAT1 signaling without affecting STAT3. Functionally, these Breg cells suppressed TH1, TH2, and TH17 responses in an IL-10-dependent manner without expanding Foxp3+ regulatory T cells. In human peripheral blood mononuclear cells from patients with AD, AICAR restored immunometabolic coupling by increasing IL-10-producing B cells and reducing proinflammatory cytokine production. CONCLUSION: These findings identify an AMPK-mTOR-redox metabolic checkpoint that governs regulatory B-cell function and restrains AD inflammation, linking metabolic control to immune regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Jeonbuk National University Medical School, Jeonju, Korea.
- Department of Dermatology, Jeonbuk National University Medical School, Jeonju, Korea; Biomedical Research Institute of Jeonbuk National University Hospital, Institute for Medical Sciences, Jeonbuk National University, J…
- CMRI, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Korea.
- Department of Biochemistry, Chungbuk National University, Cheongju, Korea.
- Department of Immunology, Jeonbuk National University Medical School, Jeonju, Korea; Biomedical Research Institute of Jeonbuk National University Hospital, Institute for Medical Sciences, Jeonbuk National University, Je…
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
Zitieren
APA
Lee, S. T., Kim, H. E., Kim, S. Y., Lee, J. Y., Nam, K. H., Kim, S. H., Park, J. Y., & Choi, J. K. (2026). AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis. Journal of Allergy and Clinical Immunology, 158(5), 1333-1346. https://doi.org/10.1016/j.jaci.2026.06.015
Vancouver
Lee ST, Kim HE, Kim SY, Lee JY, Nam KH, Kim SH, et al. AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis. Journal of Allergy and Clinical Immunology. 2026;158(5):1333-1346. doi:10.1016/j.jaci.2026.06.015
BibTeX
@article{Lee2026,
author = {Lee, Seung Taek and Kim, Ha Eun and Kim, So-Yeon and Lee, Jong Yeong and Nam, Kyung-Hwa and Kim, Sang-Hyun and Park, Jun-Young and Choi, Jin Kyeong},
title = {AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {158},
number = {5},
pages = {1333--1346},
doi = {10.1016/j.jaci.2026.06.015}
}
EUVIMED